Skip to main content
Back
ESAIY logo

Eisai Co., Ltd.

Data quality: 100%
ESAIY
OTC Healthcare Drug Manufacturers - Specialty & Generic
$7.52
▲ $0.22 (3.01%)
Mkt Cap: 8.58B
Also listed as ESALF OTC
Day Range
$7.40 $7.52
52-Week Range
$5.94 $9.22
Volume
17,232
50D / 200D Avg
$7.56 / $7.52
Prev Close
$7.30

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.2 0.4
P/B 0.0 2.9
ROE % 5.4 3.8
Net Margin % 5.9 3.9
Rev Growth 5Y % 5.1 10.0
D/E 0.2 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $39.14
$37.47 – $40.69
 870 B 1
FY2026 $40.70
$38.97 – $42.31
 860 B 1

Key Takeaways

Revenue grew 5.14% annually over 5 years — modest growth
Debt/Equity of 0.22 — conservative balance sheet
Generating 7.15B in free cash flow
P/E of 0.18 — trading at a low valuation
Capital efficient — spends only 2.91% of revenue on capex
ROIC of 3.96% — low return on invested capital

Growth

Revenue Growth (5Y)
5.14%
Revenue (1Y)6.42%
Earnings (1Y)9.49%
FCF Growth (3Y)N/A

Quality

Return on Equity
5.41%
ROIC3.96%
Net Margin5.88%
Op. Margin6.89%

Safety

Debt / Equity
0.22
Current Ratio1.95
Interest Coverage15.45

Valuation

P/E Ratio
0.18
P/B Ratio0.01
EV/EBITDA-1.28
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6.42% Revenue Growth (3Y) 2.98%
Earnings Growth (1Y) 9.49% Earnings Growth (3Y) -8.48%
Revenue Growth (5Y) 5.14% Earnings Growth (5Y) 2.58%
Profitability
Revenue (TTM) 789.40B Net Income (TTM) 46.43B
ROE 5.41% ROA 3.35%
Gross Margin 78.62% Operating Margin 6.89%
Net Margin 5.88% Free Cash Flow (TTM) 7.15B
ROIC 3.96% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.22 Current Ratio 1.95
Interest Coverage 15.45 Dividend Yield 0.04%
Valuation
P/E Ratio 0.18 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 2.36
EV/EBITDA -1.28 Dividend Yield 0.04%
Market Cap 8.58B Enterprise Value -69.46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 789.40B 741.75B 744.40B 756.23B 645.94B
Net Income 46.43B 42.41B 55.43B 47.95B 41.94B
EPS (Diluted) 40.94 36.97 48.33 41.81 36.73
Gross Profit 620.59B 586.42B 566.57B 581.40B 484.63B
Operating Income 54.38B 53.41B 40.04B 53.75B 53.22B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 1.39T 1.39T 1.26T 1.24T 1.09T
Total Liabilities 520.58B 494.82B 440.78B 467.78B 362.07B
Shareholders' Equity 841.42B 875.61B 799.96B 748.82B 703.18B
Total Debt 187.52B 159.41B 126.11B 94.89B 89.89B
Cash & Equivalents 265.56B 304.68B 267.35B 309.63B 248.74B
Current Assets 727.66B 722.98B 622.20B 640.61B 518.34B
Current Liabilities 372.29B 304.47B 298.95B 313.33B 256.02B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#105 of 820
63
Value Defensive Investing (Benjamin Graham)
#315 of 708
31

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026